# MOMA-989

Source: https://onco.cc/drugs/moma-989/  
OnCo record `moma-989` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

MOMA-989 is an experimental small molecule from MOMA Therapeutics, in preclinical development for homologous recombination deficient tumours.

## Summary

MOMA-989 is a small molecule (oral) from MOMA Therapeutics. An oral, highly potent, brain-penetrant selective PARP1 inhibitor, planned for homologous recombination deficient tumours alone and with MOMA-313. Its furthest stage is preclinical development, for homologous recombination deficient tumours. No clinical trial naming it is registered on ClinicalTrials.gov. In-licensed January 2025 from an unnamed US biopharmaceutical partner; MOMA then anticipated an IND by end of 2025. No ClinicalTrials.gov study names MOMA-989 (query.intr search, 3 Nov 2026), so it is kept at preclinical. It has not been shown to work in people.

## Fields

- Kind: Treatment
- Status: preclinical
- Last checked: 2026-11-03
- Tags: pipeline
- Code: MOMA-989
- Modality: Small molecule (oral)
- Mechanism: An oral, highly potent, brain-penetrant selective PARP1 inhibitor, planned for homologous recombination deficient tumours alone and with MOMA-313.

## Sources

- MOMA Therapeutics: momatx.com: https://momatx.com/posts/moma-therapeutics-provides-corporate-update-and-announces-exclusive-license-agreement-for-selective-parp1-inhibitor/
- MOMA Therapeutics: momatx.com: https://momatx.com/posts/moma-therapeutics-provides-corporate-update-and-announces-exclusive-license-agreement-for-selective-parp1-inhibitor/

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- targets: [PARP](https://onco.cc/targets/parp/)
- companies: [MOMA Therapeutics](https://onco.cc/companies/moma-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/moma-989.json